NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2 + breast cancer

Samuel A. Jacobs,André Robidoux,Jame Abraham,Jose Perez-Garcia,Nicla La Verde,James M. Orcutt,Marina Elena Cazzaniga,Fanny Piette,Silvia Antolín,Elena Aguirre,Javier Cortes,Antonio Llombart-Cussac,Serena Di Cosimo,Rim S. Kim,Huichen Feng,Corey Lipchik,Peter C. Lucas,Ashok Srinivasan,Ying Wang,Nan Song,Patrick G. Gavin,April D. Balousek,Soonmyung Paik,Carmen J. Allegra,Norman Wolmark,Katherine L. Pogue-Geile

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2 + breast cancer

2019

Purpose The primary aim of NSABP FB-7 was to determine the pathologic complete response (pCR) rate in locally advanced HER2-positive (HER2+) breast cancer patients treated with neoadjuvant trastuzumab or neratinib or the combination and weekly paclitaxel followed by standard doxorubicin plus cyclophosphamide. The secondary aims include biomarker analyses.

Keywords:

Doxorubicin
Breast cancer
Cancer research
Cyclophosphamide
Trastuzumab
Medicine
Paclitaxel
Oncology
Chemotherapy
Neratinib
Internal medicine
Surgical oncology
Biomarker (medicine)

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations